NPJ breast cancer 2017
Dramatic response of metaplastic breast cancer to chemo-immunotherapy.
ABSTRACT
Frequent overexpression of programmed death-ligand 1 has recently been demonstrated in metaplastic breast cancer, which is a rare breast cancer subtype with limited treatment options. This report describes the clinical course of a patient with metastatic metaplastic breast cancer who had a remarkable response to anti-programmed death-1 therapy with pembrolizumab in combination with nab-paclitaxel. Tissue correlates are presented including tumor-infiltrating lymphocytes and high-programmed death-ligand 1 expression in the tumor.
Related Questions
Patient has grade 3, pT3N0 disease and is s/p lumpectomy.
New answer by Medical Oncologist at UPMC Cancer Center (November 21, 2019)
Given these tumors tend to frequently overexpress PDL1+ and show evidence of TIL, I would strongly encourage enrollment in clinical trials which include neoadjuvant immunother...
New answer by Medical Oncologist at Mayo Clinic (December 4, 2020)
This is a tough and controversial situation, and hard to reach a consensus due to the paucity of prospective data specifically focused on this subtype. The data available sugg...